Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 10;5(1):e73-e80.
doi: 10.1055/s-0040-1722707. eCollection 2021 Jan.

Inferior Vena Cava Filter Retrieval Trends: A Single-Center Experience

Affiliations

Inferior Vena Cava Filter Retrieval Trends: A Single-Center Experience

Filip Ionescu et al. TH Open. .

Abstract

Recognition of the adverse events of inferior vena cava filters (VCFs) has prompted the Food and Drug Administration (FDA) to issue safety warnings (2010 and 2014), advocating for removal, once the risk of pulmonary embolism has abated. Despite an initial increase in retrieval rates, these remain low (25-30% at 1 year in 2014). We retrospectively investigated retrieval trends in adults with VCFs placed between 2015 and 2018 at a single institution. The rate of retrievable VCF removal accounting for the competing risk of death was the main outcome. There were 494 VCFs placed (305 retrievable). The cumulative incidence of retrieval remained low (21% at 1 year), even after the second FDA warning (2014). Patients who resumed anticoagulation (AC) at any time were more likely to have retrieval (hazard ratio [HR] = 3.6, p < 0.01) and had higher retrieval rates at every time point (31.4 vs. 7.6% at 1 year). Advanced age (HR = 0.98 per year, p = 0.004), stroke (HR = 0.28, p = 0.028), and active malignancy (HR = 0.42, p = 0.006) predicted nonretrieval. Device-related complications were infrequent (<1%) but thrombotic complications occurred early and were more common for nonretrieved VCFs (17 vs. 12%, p = 0.29). Revision of guidelines to recommend active surveillance for the ability to tolerate AC in the immediate postimplantation period may improve retrieval rates.

Keywords: IVC filter; filter failure; practice trends; retrieval; thrombosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

Fig. 1
Fig. 1
Outline of study population. pVCF, permanent vena cava filter; rVCF, retrievable VCF.
Fig. 2
Fig. 2
Indications for VCF placement in overall population. AC, anticoagulation; VCF, vena cava filter; VTE, venous thromboembolism.
Fig. 3
Fig. 3
( A ) Cumulative incidence of VCF retrieval over 2-year follow-up accounting for death as a competing risk in overall retrievable filter population. VCF, vena cava filter; VTE, venous thromboembolism. ( B ) Cumulative incidence of VCF retrieval over 2-year follow-up accounting for death as a competing risk in retrievable filter population who ever resumed AC versus who never resumed AC. AC, anticoagulation; rVCF, retrievable vena cava filter; VTE, venous thromboembolism.

References

    1. Stein P D, Matta F. Vena cava filters in unstable elderly patients with acute pulmonary embolism. Am J Med. 2014;127(03):222–225. - PubMed
    1. RIETE Investigators . Muriel A, Jiménez D, Aujesky D. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. 2014;63(16):1675–1683. - PubMed
    1. White R H, Brunson A, Romano P S, Li Z, Wun T. Outcomes after vena cava filter use in noncancer patients with acute venous thromboembolism: a population-based study. Circulation. 2016;133(21):2018–2029. - PubMed
    1. Sarosiek S, Rybin D, Weinberg J, Burke P A, Kasotakis G, Sloan J M. Association between inferior vena cava filter insertion in trauma patients and in-hospital and overall mortality. JAMA Surg. 2017;152(01):75–81. - PubMed
    1. Turner T E, Saeed M J, Novak E, Brown D L. Association of inferior vena cava filter placement for venous thromboembolic disease and a contraindication to anticoagulation with 30-day mortality. JAMA Netw Open. 2018;1(03):e180452. - PMC - PubMed